FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of FibroBiologics in a report issued on Wednesday, October 30th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.09) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for FibroBiologics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for FibroBiologics' Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at ($0.73) EPS and FY2028 earnings at ($0.70) EPS.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09).
Other equities research analysts have also recently issued reports about the stock. Maxim Group began coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a "buy" rating and a $12.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a "strong-buy" rating in a research report on Wednesday, September 4th.
Check Out Our Latest Stock Analysis on FBLG
FibroBiologics Stock Performance
Shares of NASDAQ FBLG traded up $0.14 during midday trading on Friday, hitting $3.16. 351,173 shares of the company's stock were exchanged, compared to its average volume of 260,182. The stock's 50 day moving average price is $2.69 and its 200-day moving average price is $5.49. FibroBiologics has a twelve month low of $1.08 and a twelve month high of $55.00.
Institutional Trading of FibroBiologics
Several institutional investors have recently modified their holdings of the company. Fund Evaluation Group LLC bought a new stake in FibroBiologics in the second quarter worth about $5,265,000. Cascade Financial Partners LLC bought a new stake in shares of FibroBiologics in the 2nd quarter worth approximately $1,572,000. Transform Wealth LLC acquired a new stake in FibroBiologics during the second quarter valued at approximately $668,000. Bank of New York Mellon Corp bought a new stake in FibroBiologics during the second quarter worth approximately $342,000. Finally, RMR Wealth Builders acquired a new position in FibroBiologics in the second quarter worth approximately $186,000.
About FibroBiologics
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Featured Stories
Before you consider FibroBiologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroBiologics wasn't on the list.
While FibroBiologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
